5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Pipeline Review, H2 2017

  • ID: 4446880
  • Report
  • 67 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Adamed Sp z oo
  • Astellas Pharma Inc
  • H. Lundbeck AS
  • Johnson & Johnson
  • MORE
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Pipeline Review, H2 2017

Summary

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report 5-Hydroxytryptamine Receptor 7 - Pipeline Review, H2 2017, outlays comprehensive information on the 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - 5-HT7 receptor is a member of the GPCR superfamily and it is activated by the serotonin (5-HT). The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It plays an important role in autistic disorder and other neuropsychiatric disorders. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2, 1 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular and Genetic Disorders which include indications Psychiatric Disorders, Bipolar Disorder (Manic Depression), Major Depressive Disorder, Schizophrenia, Attention Deficit Hyperactivity Disorder (ADHD), Autism, Anxiety Disorders, Cognitive Disorders, Fragile X Syndrome, Inflammatory Pain, Migraine, Neuropathic Pain, Pervasive Developmental Disorder (PDD), Psychosis, Pulmonary Arterial Hypertension, Schizoaffective Disorder, Social Anxiety Disorders (SAD) and Tourette Syndrome.

Furthermore, this report also reviews key players involved in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)
  • The report reviews 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics and enlists all their major and minor projects
  • The report assesses 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Adamed Sp z oo
  • Astellas Pharma Inc
  • H. Lundbeck AS
  • Johnson & Johnson
  • MORE
Introduction

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Overview

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Companies Involved in Therapeutics Development

Adamed Sp z oo

Astellas Pharma Inc

Braeburn Pharmaceuticals Inc

H. Lundbeck AS

Johnson & Johnson

Reviva Pharmaceuticals Inc

Sumitomo Dainippon Pharma Co Ltd

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Drug Profiles

ADN-1184 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADN-3662 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-9242 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DDD-028 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-18038683 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lurasidone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-5063 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SERx-519 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Alpha 2 Adrenergic Receptor and Antagonize 5-HT7 and 5-HT5A Receptors for Psychiatric Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for Migraine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vortioxetine hydrobromide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Dormant Products

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Discontinued Products

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Product Development Milestones

Featured News & Press Releases

Dec 04, 2017: Lundbeck’s Brintellix approved in China

Oct 27, 2017: Sunovion Presents Data from Phase 3 Studies of Latuda (lurasidone HCl) in Children and Adolescents with Bipolar Depression

Oct 17, 2017: Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting With FDA on RP5063 for the Treatment of Pulmonary Arterial Hypertension

Sep 14, 2017: Sunovion to Present Data on LATUDA at the 2017 Psych Congress

Jul 21, 2017: Sunovion’s Latuda (lurasidone HCI) Receives Health Canada Approval to Treat Adolescents with Schizophrenia

Jun 30, 2017: Sunovion Announces FDA Acceptance for Review of Supplemental New Drug Application for Latuda for the Treatment of Bipolar Depression in Children and Adolescents

Jun 23, 2017: Lundbeck and Takeda receive Complete Response Letter from the FDA for Trintellix (vortioxetine) sNDA

Jun 23, 2017: Lundbeck and Takeda receive Complete Response Letter from the FDA for Trintellix sNDA

Jun 09, 2017: Sumitomo Dainippon Pharma Announces Topline Results from a Phase 3 Study of Lurasidone, an Atypical Antipsychotic Agent, in the Treatment of Patients with Bipolar l Depression

May 22, 2017: Sunovion Announces Positive Results from Study Evaluating Latuda (lurasidone HCl) in Children and Adolescents with Bipolar Depression at Annual American Psychiatric Association Meeting

May 16, 2017: Sunovion to Present Data on Latuda (lurasidone HCl) at Annual American Psychiatric Association Meeting

Mar 31, 2017: Sunovion to Present Data on LATUDA (lurasidone HCI) at the 25th European Congress of Psychiatry

Feb 27, 2017: Sunovion Announces Positive Topline Results from Study Evaluating Latuda (lurasidone HCl) in Children and Adolescents with Bipolar Depression

Jan 28, 2017: Sunovion’s Latuda (lurasidone HCl) Receives FDA Approval to Treat Adolescents with Schizophrenia

Dec 02, 2016: Sunovion to Present Data on Latuda (lurasidone HCl) at the 55th Annual Meeting of the American College of Neuropsychopharmacology

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2

Number of Products under Development by Therapy Areas, H2

Number of Products under Development by Indication, H2

Number of Products under Development by Companies, H2

Products under Development by Companies, H2

Products under Development by Companies, H2 2017 (Contd..1), H2

Number of Products under Investigation by Universities/Institutes, H2

Products under Investigation by Universities/Institutes, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Pipeline by Adamed Sp z oo, H2

Pipeline by Astellas Pharma Inc, H2

Pipeline by Braeburn Pharmaceuticals Inc, H2

Pipeline by H. Lundbeck AS, H2

Pipeline by Johnson & Johnson, H2

Pipeline by Reviva Pharmaceuticals Inc, H2

Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2

Dormant Projects, H2

Discontinued Products, H2

List of Figures

Number of Products under Development by Stage of Development, H2

Number of Products under Development by Therapy Areas, H2

Number of Products under Development by Top 10 Indications, H2

Number of Products by Mechanism of Actions, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Stage and Molecule Type, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Adamed Sp z oo
  • Astellas Pharma Inc
  • Braeburn Pharmaceuticals Inc
  • H. Lundbeck AS
  • Johnson & Johnson
  • Reviva Pharmaceuticals Inc
  • Sumitomo Dainippon Pharma Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll